Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
KRASG13C
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "KRASG13C" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-18707
CAS No.: 1469337-95-8
K-Ras(G12C) inhibitor 12 is an irreversible inhibitor of K-Ras(G12C). K-Ras(G12C) inhibitor 12 can alter the nucleotide-binding preference of K-Ras and block its interaction with effector proteins. K-Ras(G12C) inhibitor 12 can reduce cell viability and induce apoptosis in lung cancer cell lines with G12C mutations. K-Ras(G12C) inhibitor 12 has anti-tumor activity .
Cat. No.: HY-12446
CAS No.: 1469337-91-4
K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C) .
Cat. No.: HY-173252
Research Areas:
KRASG12C ligand-1 is a PROTAC target protein ligand that can be used to synthesize the PROTAC YN14-H (HY-173250). YN14-H is a PROTAC degrader targeting KRAS G12C and has antitumor activity .
Cat. No.: HY-175583
CAS No.: 2725905-93-9
Research Areas:
KRASG12C ligand-2 is a KRas ligand used for PROTAC synthesis. KRASG12C ligand-2 serves as the target protein ligand of PROTAC KRAS G12C degrader-2 (HY-153821) .
Cat. No.: HY-179484
CAS No.: 2915282-32-3
Target:
Research Areas:
KRASG12C IN-19 is a selective and orally active KRAS G12C inhibitor. KRASG12C IN-19 exerts potent antiproliferative activity against the KRAS G12C-mutant non small cell lung cancer (NSCLC) cell line H358 with an IC50 of 7.6 nM, and effectively suppresses downstream ERK phosphorylation (IC50 = 24.06 nM). KRASG12C IN 19 has no significant inhibitory activity against KRAS G12V and KRAS G12D-mutant cancer cells (PANC 1, Panc, AsPC 1, and GP2d cells) with IC50 > 10,000 nM. KRASG12C IN-19 rapidly forms a covalent bond with KRAS G12V-GDP, leading to dose-dependent inhibition of the downstream KRAS pathway. KRASG12C IN 19 can be employed for research in KRAS G12C driven cancers, including non small cell lung cancer, pancreatic cancer, and colorectal cancer .
Cat. No.: HY-182883
KRASG12C IN-20 is an orally potent KRAS G12C inhibitor with an EC50 of 3.9 nM. KRASG12C IN-20 covalently modifies KRAS G12C in its inactive GDP-bound state and locks it to block oncogenic signal transduction. KRASG12C IN-20 exhibits significant activity in lung adenocarcinoma xenograft models. KRASG12C IN-20 can be used for research related to lung adenocarcinoma .
Cat. No.: HY-P705319
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A*0201; B2M; KRASG12C (KLVVVGACGV)
Species:
Human
Source:
HEK293
Cat. No.: HY-P705349
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A*0301; B2M; KRASG12C (VVGACGVGK)
Species:
Human
Source:
HEK293
Cat. No.: HY-P705350
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A*0301; B2M; KRASG12C (VVVGACGVGK)
Species:
Human
Source:
HEK293
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
